Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | XDH | P47989 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282481 | 0.87 | KDM4E (0.63) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL5924237 | 0.87 | KDM4E (0.63) | KDM4EGAAXDHLMNAPOLB | |
| Hydrochloric Acid SCHEMBL9064595 | 0.85 | KDM4E (0.61) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL30073372 | 0.84 | KDM4E (0.51) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL29406911 | 0.84 | KDM4E (0.51) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL1758897 | 0.84 | KDM4E (0.51) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL28708997 | 0.84 | KDM4E (0.51) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL18585192 | 0.82 | KDM4E (0.50) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL8539124 | 0.81 | XDH (0.74) | KDM4EGAAXDHLMNAPOLB | |
| SCHEMBL2663753 | 0.81 | GAA (0.74) | KDM4EGAAXDHLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| EP-4678640-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024188086-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3283077-A2 | BROMODOMAIN INHIBITOR | Celgene Quanticel Research, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | KDM4E 623/4885GAA 1357/4885XDH 3270/4885 |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | KDM4E 2522/4885GAA 2145/4885XDH 63/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | KDM4E 2522/4885GAA 2145/4885XDH 63/4885 |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | KDM4E 4010/4885GAA 4548/4885XDH 2480/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | KDM4E 1536/4885GAA 4457/4885XDH 183/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | KDM4E 133/4885GAA 2967/4885XDH 3177/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885XDH 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.